OncoSec looks to boost effects of immunotherapy with intratumoral delivery – Mass Device
Mass Device |
OncoSec looks to boost effects of immunotherapy with intratumoral delivery
Mass Device Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body's immune system from acting in the … |
